A phase II evaluation of elesclomol sodium and weekly paclitaxel in the treatment of recurrent or persistent platinum-resistant ovarian, fallopian tube or primary peritoneal cancer: An NRG oncology/gynecologic oncology group study
Authors:
- Bradley J. MonkBMBradley J. Monk
- James T. KaudererJKJames T. Kauderer
- Katherine M. MoxleyKMKatherine M. Moxley
- Albert J. BonebrakeABAlbert J. Bonebrake
- Summer B. DewdneySDSummer B. Dewdney
- Angeles Alvarez SecordASAngeles Alvarez Secord
- Frederick R. UelandFUFrederick R. Ueland
- Carolyn M. JohnstonCJCarolyn M. Johnston
- Carol AghajanianCACarol Aghajanian
- 1 December 2018
- journal article
- research article
- Published by Elsevier in Gynecologic Oncology
- Vol. 151 (3) , 422-427
Abstract
No abstract availableKeywords
Funding Information
- National Cancer Institute (CA 27469)
- Gynecologic Oncology Group Statistical and Data Center (CA 37517)
- NRG Oncology (1 U10 CA180822)
- NRG Operations (U10CA180868)
This publication has 13 references indexed in Scilit:
- Bringing new medicines to women with epithelial ovarian cancer: what is the unmet medical need?Gynecologic Oncology Research and Practice, 2017
- Cellular mechanisms of the cytotoxicity of the anticancer drug elesclomol and its complex with Cu(II)Biochemical Pharmacology, 2015
- Final Results of Phase III SYMMETRY Study: Randomized, Double-Blind Trial of Elesclomol Plus Paclitaxel Versus Paclitaxel Alone As Treatment for Chemotherapy-Naive Patients With Advanced MelanomaJournal of Clinical Oncology, 2013
- Latest research and treatment of advanced-stage epithelial ovarian cancerNature Reviews Clinical Oncology, 2013
- A phase II evaluation of nab-paclitaxel in the treatment of recurrent or persistent platinum-resistant ovarian, fallopian tube, or primary peritoneal cancer: A Gynecologic Oncology Group (GOG) study.Journal of Clinical Oncology, 2010
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)European Journal of Cancer, 2009
- A phase II trial of paclitaxel poliglumex in recurrent or persistent ovarian or primary peritoneal cancer (EOC): A gynecologic oncology group studyGynecologic Oncology, 2008
- Phase I Clinical Trial of STA-4783 in Combination with Paclitaxel in Patients with Refractory Solid TumorsClinical Cancer Research, 2007
- Phase II trial of weekly paclitaxel (80 mg/m2) in platinum and paclitaxel-resistant ovarian and primary peritoneal cancers: A Gynecologic Oncology Group studyGynecologic Oncology, 2006
- A phase II study of docetaxel in paclitaxel-resistant ovarian and peritoneal carcinoma: a gynecologic oncology group studyGynecologic Oncology, 2003